PTO/SB/08A (07-05)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

. (Use as many sheets as necessary)

of 2

Complete if Known				
Application Number	10/533,838			
Filing Date	May 4, 2005			
First Named Inventor	Brown			
Art Unit	1614			
Examiner Name	Unknown			
Attorney Docket Number	100885-1P US			

	1			Name of Patentee or	Pages, Columns, Lines, Where	
Examiner City Initials* No.	Cite No.	Document Number	Publication Date MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevan Figures Appear	
		Number-Kind Code <sup>2 (F known)</sup>				
/BR/		<sup>US-</sup> 2,898,339	08-04-1959	Wheeler et al.		
KANK		<sup>US-</sup> 4,581,171	04-08-1986	Kennis et al.		
PANK		<sup>US-</sup> 4,816,586	03-28-1989	Portoghese		
CAMIL		<sup>US-</sup> 4,939,137	07-03-1990	Russell et al.		
BONN		<sup>US-</sup> 5,140,029	08-18-1992	Kennis et al.		
ZW		<sup>US-</sup> 5,574,159	11-12-1996	Chang et al.		
MIL		<sup>US-</sup> 5,683,998	11-04-1997	Shibayama et al.		
MIK.		us- 6,187,792	02-13-2001	Delorme et al.	•	
MAT		<sup>US-</sup> 6,455,545	09-24-2002	Delorme et al.		
10.4		US-				
<u> </u>		US-				
····		US-				
	<del> </del>	US-				
		US-				
		US-				
		US-				
	† ·	US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS						
Examiner Cite Foreign Patent Document No.1 Country Code3 Number 4 Kind Code5 (if known)			Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
	MM-DD-YYYY		Or Relevant Figures Appear	1		
BUIL		WO 93/15062	08-05-1993	The Wellcome Foundation		
WILL		WO 97/23466	07-03-1997	Astra Aktiebolag		
DIL		WO 98/28275	07-02-1998	Astra Pharma Inc.		
BUIL		WO 99/33806	07-08-1999	Ortho-McNeil Pharmaceutic		
RANK		WO 01/74804	10-11-2001	AstraZeneca AB		
BALL		WO 01/74806	10-11-2001	AstraZeneca AB		

			والمستحد والمراجع فالمجارية والمسادر والمستحيظ والمفاق تتهيها والمستحد
Examiner Signature	/Binta Robinson/	Date Considered	05/11/2007

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.goy">www.uspto.goy</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 If possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in compléting the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction For Town Institute of Town Institute				Complete if Known		
Substitu	ite for form 1449/PT	O		Application Number	10/533,838	
INF	ORMATIC	N DIS	CLOSURE	Filing Date	May 4, 2005	
STATEMENT BY APPLICANT				First Named Inventor	Brown	
				Art Unit	1614	
(Use as many sheets as necessary)		Examiner Name	Unknown ·			
Sheet	2	of	2	Attorney Docket Number	100885-1P US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
fame		BARBER, A. et al., "Antinociceptive effects of the 5-HT2 Antagonist Ritanserin in Rats: Evidence in the Spinal Cord," Neuroscience Letters, 1989, Vol. 99, pgs 234-238	
AMIL		BILSKY, E. et al., "SNC 80, A Selective, Nonpeptidic and Systematically Active Opioid Delta Agonist," J. Pharmacology Experimental Ther., 1995, Vol. 273, pgs. 359-366	
PAM		GREENE T., "Protective Groups in Organic Synthesis," Wiley & Sons, 1982, pgs. 218, 220, 232, 233, 251	
AMC	•	TAKEMORI, A.E. et al., "Selective Natrexone-Derived Opioid Receptor Antagonists," Annu. Rev. Pharmacol. Toxicol., 1992, Vol. 32, pgs. 239-269	
BMC		WEI, Z. et al., "N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide A Novel and its Analogues," J. Med. Chem., 2000, Vol. 43, pgs. 3895-3905	
SIM		ZHANG, X. et al., *Probes for Narcotic Receptor Mediated Phenomena. 26. 1-3 Synthesis Oploid Receptor Ligands, J. Med. Chem., 1999, Vol. 42, pgs. 5455-5463	
<i>12-7</i> 5	<del></del>		
		•	

Examiner	2/2//	Date	(121/	13/7
Signature	Kinto Hourson	Considered	0/1/	UP

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.